论文部分内容阅读
对于脑梗死的治疗,日本于2005年应用组织型纤溶酶原激活物(t-PA)的溶栓疗法,2006年氯吡格雷(clopidogvel)成为保险适用。国际性大规模病例登记试验REACH开始启动,并完成首份报告。有报道称正常高值血压使心血管意外增加,给予ARB治疗可以预防高血压发病。研究显示糖化血红蛋白(HbA1C)与脑梗死发病相关,有报道称吡格列酮(pio-glitazone)治疗糖尿病可降低心血管意外和死亡的发生。对日本人采用他汀类药物治疗的大规模临床试验MEGAStudy显示对脑卒中有预防效果,SPARCLE报道他汀类药物具有预防卒中复发的效果。
For the treatment of cerebral infarction, Japan in 2005 with tissue-type plasminogen activator (t-PA) thrombolytic therapy, 2006 clopidogrel (clopidogvel) become insurance applicable. International large-scale case registration test REACH started, and completed the first report. It has been reported that normal high blood pressure causes cardiovascular accidents, given ARB treatment can prevent the incidence of hypertension. Studies have shown that HbA1C is associated with the onset of cerebral infarction. It has been reported that the treatment of diabetes with pio-glitazone reduces cardiovascular accidents and deaths. MEGAStudy, a large-scale clinical trial of statins in Japan, has shown prophylactic effects on stroke, and SPARCLE reports that statins have the effect of preventing recurrent stroke.